Puma Biotechnology (PBYI) Change in Account Payables (2011 - 2026)

Puma Biotechnology (PBYI) has 16 years of Change in Account Payables data on file, last reported at $3.1 million in Q1 2026.

• Quarterly Change in Account Payables rose 501.55% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 172.84% YoY) and the FY2025 annual result came in at -$453000.0, up 67.17% from the prior year.
• Change in Account Payables advanced to $3.1 million in Q1 2026, from -$1.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $5.1 million in Q3 2022 to a low of -$8.5 million in Q4 2022.
• A 5-year average of -$176941.2 and a median of $517000.0 in 2025 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 671.28% in 2024, down 209.41% in 2024.
• Tracing PBYI's Change in Account Payables over 5 years: stood at -$8.5 million in 2022, then surged by 121.54% to $1.8 million in 2023, then slumped by 209.41% to -$2.0 million in 2024, then jumped by 33.5% to -$1.3 million in 2025, then jumped by 333.83% to $3.1 million in 2026.
• The last three Change in Account Payables figures came in at $3.1 million (Q1 2026), -$1.3 million (Q4 2025), and $962000.0 (Q3 2025), per Business Quant data.